362 related articles for article (PubMed ID: 36232447)
1. Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.
Boutilier AJ; Huang L; Elsawa SF
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232447
[TBL] [Abstract][Full Text] [Related]
2. Targeting the bone marrow in Waldenstrom macroglobulinemia.
Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa GC; Leleu X; Roccaro AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S65-9. PubMed ID: 22035751
[TBL] [Abstract][Full Text] [Related]
3. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract][Full Text] [Related]
6. The bone marrow microenvironment in Waldenström macroglobulinemia.
Agarwal A; Ghobrial IM
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):218-21. PubMed ID: 23490994
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment options for Waldenström macroglobulinemia.
Leblebjian H; Agarwal A; Ghobrial I
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
[TBL] [Abstract][Full Text] [Related]
9. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
10. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.
Sun H; Fang T; Wang T; Yu Z; Gong L; Wei X; Wang H; He Y; Liu L; Yan Y; Sui W; Xu Y; Yi S; Qiu L; Hao M
J Transl Med; 2022 Dec; 20(1):576. PubMed ID: 36494694
[TBL] [Abstract][Full Text] [Related]
11. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
Cholujova D; Beke G; Hunter ZR; Hideshima T; Flores L; Zeleznikova T; Harrachova D; Klucar L; Leiba M; Drgona L; Treon SP; Kastritis E; Dorfman DM; Anderson KC; Jakubikova J
Int J Cancer; 2023 May; 152(9):1947-1963. PubMed ID: 36533670
[TBL] [Abstract][Full Text] [Related]
12. Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation.
Brysland SA; Maqbool MG; Talaulikar D; Gardiner EE
Thromb Haemost; 2022 Nov; 122(11):1843-1857. PubMed ID: 35817084
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
14. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
15. Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual.
Wang E; Kulbacki E; Stoecker M
Hum Pathol; 2012 Jul; 43(7):1135-41. PubMed ID: 22404949
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Sacco A; Ghobrial IM; Roccaro AM
Curr Cancer Drug Targets; 2011 Nov; 11(9):1025-9. PubMed ID: 21933107
[TBL] [Abstract][Full Text] [Related]
17. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
18. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
[TBL] [Abstract][Full Text] [Related]
19. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract][Full Text] [Related]
20. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]